Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation
- 1 March 2022
- journal article
- research article
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (11) , 2789-2802
Abstract
Objective High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastasis and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAF(V600E) mutation to screen high-risk PTC at early stage. Methods The targeted lipid nanobubbles carrying BRAF(V600E) antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAF(V600E) were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAF(V600E) were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging. Results The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAF(V600E) monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAF(V600E) overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAF(V600E) overexpression as compared to the untargeted lipid nanobubbles. Conclusion The targeted lipid nanobubbles carrying BRAF(V600E) antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.Keywords
This publication has 44 references indexed in Scilit:
- Cyanine 5.5 Conjugated Nanobubbles as a Tumor Selective Contrast Agent for Dual Ultrasound-Fluorescence Imaging in a Mouse ModelPLOS ONE, 2013
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid CancerJAMA, 2013
- Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 CasesAnnals of Surgical Oncology, 2013
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI: Journal of the National Cancer Institute, 2013
- A combined molecular‐pathologic score improves risk stratification of thyroid papillary microcarcinomaCancer, 2011
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancerCancer, 2011
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibodyActa Neuropathologica, 2011
- Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult MouseCancer Research, 2011
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo DedifferentiationCancer Research, 2005